Table 1.
Baseline clinicopathologic characteristics at the time of tumorgraft generation
| XPID | XP258 | XP490 | XP783 | XP813 | XP818 | XP925 | XP945 | XP955 |
|---|---|---|---|---|---|---|---|---|
| Sex | F | M | M | M | M | M | M | F |
| Race | Black | White | White | White | White | White | White | White |
| Ethnicity | Non-Hispanic | Non-Hispanic | Hispanic | Non-Hispanic | Non-Hispanic | Non-Hispanic | Non-Hispanic | Hispanic |
| Age (years) | 50 | 64 | 56 | 57 | 52 | 58 | 49 | 63 |
| Tumor Source | Primary | Primary | Metastasis | Metastasis | Metastasis | Metastasis | Primary | Primary |
| Tumor Site | Kidney | Kidney | Bone | Spinal Cord | Spinal Cord | RP mass | Adrenala | Tumor Thrombus |
| Histology | ccRCC | ccRCC | ccRCC | ccRCC | ccRCC | pRCC | ccRCC | ccRCC |
| pT stage | 3a | 3a | N/A | N/A | N/A | N/A | 4 | 3a |
| Grade | 4 | 4 | 4 | 3 | 3 | 3 | 4 | 4 |
| Sarcomatoid Features | Yes | Yes | Yes | No | No | No | Yes | No |
| Rhabdoid Features | No | Yes | No | No | No | No | No | No |
| Prior Treatment | None | None | Pazo | Pazo, Eve, Axi, Bev, Nivo | HDIL2, Axi, Nivo, Nivo+Ipi | None | None | None |
| PD-L1 IHC % (Patient Tumor) | 0 | 25 | 50 | 0 | 1 | 15 | 30 | 75–80 |
| PD-L1 IHC % (TG) b | 1–10 | 40–75 | 60–85 | 1–5 | 0 | 10–15 | 40–70 | 60–70 |
a:
via direct invasion of primary tumor
b:
range represents variation in PD-L1 expression across mice within the same XP line (i.e., derived from the same parent tumor).
Abbreviations: Axi, axitinib; Bev, bevacizumab; Eve, everolimus; F, female; HDIL2, high dose Interleukin 2; Ipi, ipilimumab; M, male; N/A, Not Applicable; Nivo, nivolumab; pRCC, papillary renal cell carcinoma; Pazo, pazopanib; pT, pathologic T stage; RP, retroperitoneal; XPID, xenograft project ID.